More importantly, the in vitro effect of rhCD137L-MSNs is particularly pronounced when tumor cells express CD137, highlighting that dual targeting of CD137 on both tumor cells and T cells synergistically maximizes the T cell-mediated anti-tumor immune response. The gene discussed is TNFRSF9; the disease is neoplasm.